NTC ACQUIRES FROM NMTECH UK TiAb AND SIAB BASED TECHNOLOGY

  • June 12, 2019

Milan, Italy, June 12, 2019 – NTC focuses on strengthening its gynecology, dermatology and ophthalmology portfolio and pipeline.

NEW LIFE FOR PATIENTS SUFFERING FROM BLEPHARITIS: a controlled clinical study was presented on Blefastop, an ocular and periocular innovative therapeutic solution as adjuvant in blepharitis.

  • June 5, 2019

Milan, June 5, 2019 – Recently, a controlled clinical study was presented on Blefastop, an ocular and periocular innovative therapeutic solution as adjuvant in blepharitis.

NTC grants further license and distribution rights to Santen for its fixed combination dexamethasone with levofloxacin in South East Asia

  • May 22, 2019

Milan, Italy, May 22, 2019 – NTC Srl, R&D driven pharmaceutical company with headquarters in Italy, and Santen Pharmaceutical Co. Ltd, a global leader in ophthalmology, announce today the extension of their original agreement for Europe signed in December 2017.

NTC closes a deal with Bruno Farmaceutici for the development of a new solution to treat external and medium otitis with tympanostomy in children.

  • Feb 26, 2019

Milan, February 26th 2019 – NTC Srl, an Italian pharmaceutical company with significant expertise in research and development in ophthalmology, announces today a commercial partnership with Bruno Farmaceutici S.p.A.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. READ MORE